SCHEMBL4211673

SCHEMBL4211673

CONC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)cc3)cc2)ccn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 14/20 0.59
EPHX2 P34913 3/20 0.59
KDR P35968 7/20 0.58
MAPK14 Q16539 3/20 0.58
PLK4 O00444 2/20 0.58
AURKA O14965 2/20 0.58
MAPK13 O15264 2/20 0.58
MAP4K4 O95819 2/20 0.58
ABL1 P00519 2/20 0.58
LCK P06239 2/20 0.58
FYN P06241 2/20 0.58
LYN P07948 2/20 0.58
RET P07949 2/20 0.58
SRC P12931 2/20 0.58
RPS6KB1 P23443 2/20 0.58
EPHA2 P29317 2/20 0.58
AXL P30530 2/20 0.58
FRK P42685 2/20 0.58
MAPK9 P45984 2/20 0.58
BLK P51451 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4199960 0.90 RAF1 (0.63) RAF1EPHX2KDRMAPK14PLK4
SCHEMBL4205874 0.90 KDR (0.60) RAF1EPHX2KDRMAPK14PLK4
SCHEMBL16620832 0.88 RAF1 (0.74) RAF1EPHX2KDRMAPK14PLK4
SCHEMBL13946016 0.88 RAF1 (0.61) RAF1EPHX2KDRMAPK14PLK4
SCHEMBL4205893 0.86 RAF1 (0.59) RAF1EPHX2KDRMAPK14PLK4
SCHEMBL4209263 0.85 RAF1 (0.82) RAF1EPHX2KDRMAPK14PLK4
SCHEMBL13946072 0.85 RAF1 (0.56) RAF1EPHX2KDRMAPK14PLK4
SCHEMBL13946030 0.82 RET (0.65) RAF1EPHX2KDRMAPK14PLK4
Trifluoroacetic Acid SCHEMBL19878562 0.82 RAF1 (0.74) RAF1EPHX2KDRMAPK14PLK4
SCHEMBL13945906 0.82 KDR (0.57) RAF1EPHX2KDRMAPK14PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012091-A1 Oximide derivatives and their therapeutical application KINAGEN, INC. (US) 2009-01-08 US disclosed
US-20090012091-A1 Oximide derivatives and their therapeutical application KINAGEN, INC. (US) 2009-01-08 US disclosed
US-20090012091-A1 Oximide derivatives and their therapeutical application KINAGEN, INC. (US) 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012091-A1 Oximide derivatives and their therapeutical application CYP11B2, NOS2, HMOX2 RAF1 3755/4885EPHX2 364/4885KDR 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.